2552 Stock Overview
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2552 from our risk checks.
Hua Medicine (Shanghai) Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.59 |
| 52 Week High | HK$3.15 |
| 52 Week Low | HK$1.29 |
| Beta | 1.6 |
| 1 Month Change | 2.58% |
| 3 Month Change | -20.10% |
| 1 Year Change | -48.71% |
| 3 Year Change | -67.42% |
| 5 Year Change | -77.45% |
| Change since IPO | -80.80% |
Recent News & Updates
Recent updates
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?
Nov 17
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects
Aug 28We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth
Jan 06We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow
Aug 02Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Apr 22Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Sep 23We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn
Jun 24Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Mar 22Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook
Feb 21Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year
Jan 25
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business
Dec 21Shareholder Returns
| 2552 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 5.3% | 1.8% | 2.3% |
| 1Y | -48.7% | -17.4% | -10.9% |
Return vs Industry: 2552 underperformed the Hong Kong Pharmaceuticals industry which returned -17.4% over the past year.
Return vs Market: 2552 underperformed the Hong Kong Market which returned -10.9% over the past year.
Price Volatility
| 2552 volatility | |
|---|---|
| 2552 Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.5% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2552's share price has been volatile over the past 3 months.
Volatility Over Time: 2552's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 177 | Li Chen | www.huamedicine.com |
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with insulin for late stage T2D and Type 1 Diabetes.
Hua Medicine (Shanghai) Ltd. Fundamentals Summary
| 2552 fundamental statistics | |
|---|---|
| Market cap | HK$1.56b |
| Earnings (TTM) | -HK$228.39m |
| Revenue (TTM) | HK$82.83m |
18.8x
P/S Ratio-6.8x
P/E RatioIs 2552 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2552 income statement (TTM) | |
|---|---|
| Revenue | CN¥76.61m |
| Cost of Revenue | CN¥39.24m |
| Gross Profit | CN¥37.37m |
| Other Expenses | CN¥248.61m |
| Earnings | -CN¥211.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 48.78% |
| Net Profit Margin | -275.73% |
| Debt/Equity Ratio | 122.6% |
How did 2552 perform over the long term?
See historical performance and comparison